Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

doi:10.1186/s13045-021-01077-3

Review

. 2021 Apr 21;14(1):66.

doi: 10.1186/s13045-021-01077-3.

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Jing-Zhou Hou^{1

2}, Jing Christine Ye^{3

4}, Jeffrey J Pu^{5

4}, Hongtao Liu^{6

4}, Wei Ding^{7

4}, Hong Zheng^{8

4}, Delong Liu^{9

10}

Affiliations

¹ Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC), 5115 Centre Ave., Fl 4, Pittsburgh, PA, 15232, USA. houj@upmc.edu.
² Chinese American Hematologist and Oncologist Network (CAHON), 555 East Wells Street, Suite 1100, Milwaukee, WI, 53202, USA. houj@upmc.edu.
³ Department of Internal Medicine, Hematology/Oncology Division, University of Michigan, Rogel Cancer Center, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.
⁴ Chinese American Hematologist and Oncologist Network (CAHON), 555 East Wells Street, Suite 1100, Milwaukee, WI, 53202, USA.
⁵ Department of Medicine, University of Arizona NCI Designated Comprehensive Cancer Center, Tucson, AZ, USA.
⁶ Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
⁷ Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.
⁸ Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, PA, 17033, USA.
⁹ Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA. delong_liu@nymc.edu.
¹⁰ Chinese American Hematologist and Oncologist Network (CAHON), 555 East Wells Street, Suite 1100, Milwaukee, WI, 53202, USA. delong_liu@nymc.edu.

PMID: 33879198
PMCID: PMC8059303
DOI: 10.1186/s13045-021-01077-3

Review

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Jing-Zhou Hou et al. J Hematol Oncol. 2021.

. 2021 Apr 21;14(1):66.

doi: 10.1186/s13045-021-01077-3.

Authors

Jing-Zhou Hou^{1

2}, Jing Christine Ye^{3

4}, Jeffrey J Pu^{5

4}, Hongtao Liu^{6

4}, Wei Ding^{7

4}, Hong Zheng^{8

4}, Delong Liu^{9

10}

Affiliations

¹ Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC), 5115 Centre Ave., Fl 4, Pittsburgh, PA, 15232, USA. houj@upmc.edu.
² Chinese American Hematologist and Oncologist Network (CAHON), 555 East Wells Street, Suite 1100, Milwaukee, WI, 53202, USA. houj@upmc.edu.
³ Department of Internal Medicine, Hematology/Oncology Division, University of Michigan, Rogel Cancer Center, 1500 E Medical Center Dr, Ann Arbor, MI, 48109, USA.
⁴ Chinese American Hematologist and Oncologist Network (CAHON), 555 East Wells Street, Suite 1100, Milwaukee, WI, 53202, USA.
⁵ Department of Medicine, University of Arizona NCI Designated Comprehensive Cancer Center, Tucson, AZ, USA.
⁶ Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, 5841 S. Maryland, MC 2115, Chicago, IL, 60637-1470, USA.
⁷ Division of Hematology, Mayo Clinic, Rochester, MN, 55905, USA.
⁸ Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, PA, 17033, USA.
⁹ Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA. delong_liu@nymc.edu.
¹⁰ Chinese American Hematologist and Oncologist Network (CAHON), 555 East Wells Street, Suite 1100, Milwaukee, WI, 53202, USA. delong_liu@nymc.edu.

PMID: 33879198
PMCID: PMC8059303
DOI: 10.1186/s13045-021-01077-3

Abstract

Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BCL-2, IDH1, IDH2, are biomarker-driven chemotherapy-free agents approved for several major hematological malignancies. LOXO-305, asciminib, "off-the-shelf" universal CAR-T cells and BCMA-directed immunotherapeutics as well as data from clinical trials on many novel agents and regimens were updated at the 2020 American Society of Hematology (ASH) Annual Meeting. Major developments and updates for the therapy of hematological malignancies were delineated at the recent Winter Symposium and New York Oncology Forum from the Chinese American Hematologist and Oncologist Network (CAHON.org). This study summarized the latest updates on novel agents and regimens for hematological malignancies from the 2020 ASH annual meeting.

Keywords: Antibody–drug conjugate; Asciminib; BCMA; BiTE; CAR-T; LOXO-305.

PubMed Disclaimer

Conflict of interest statement

WD attended advisory board meetings of Merck, Beigene, Alexion, Octapharma, MEI pharma, had research fundings from Merck, DTRM, AbbVie, Octapharma, AstraZeneca. JH attended advisory board meetings of AstraZeneca and Genentech. DL attended advisory board meetings of AstraZeneca, Beigene, Rigel; serves on the Speaker bureaus of AstraZeneca, Beigene, Incyte, Janssen and Pharmacyclics; and had research fundings from Acerta, Celgene, Denovo, Pfizer. HL attended advisory board meetings of Agios; and had research fundings from BMS and karyopharma. JJP attended advisory board meetings of Roche, Astellas, Incyte, Novartis; and had research fundings from Takada, Millennium, Incyte. JCY had research fundings from Janssen, GSK, Nektar, Celgene, Takeda, Karyopharm, Sanofi, Multiple Myeloma Research Foundation, CARsgen, MingSight, and Portola. HZ attended advisory board meetings of BeiGene, BMS; and had research Funding from Pfizer.

Cited by

Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes.
Yang X, Jiang L, Zhang X, Peng J, Qian H, Huang L, He S, Wang Z, Chen L, Zhang Y, Ma L, Chen Y, Wei J. Yang X, et al. Biomark Res. 2024 Oct 8;12(1):115. doi: 10.1186/s40364-024-00665-y. Biomark Res. 2024. PMID: 39379980 Free PMC article.
Therapeutic Immunomodulation in Gastric Cancer.
Akkanapally V, Bai XF, Basu S. Akkanapally V, et al. Cancers (Basel). 2024 Jan 28;16(3):560. doi: 10.3390/cancers16030560. Cancers (Basel). 2024. PMID: 38339311 Free PMC article. Review.
Targeting macrophages in hematological malignancies: recent advances and future directions.
Li W, Wang F, Guo R, Bian Z, Song Y. Li W, et al. J Hematol Oncol. 2022 Aug 17;15(1):110. doi: 10.1186/s13045-022-01328-x. J Hematol Oncol. 2022. PMID: 35978372 Free PMC article. Review.
Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center.
Zhu Y, Zhang X, Wei J, Yang C, Tong H, Mai W, Yang M, Qian J, Mao L, Meng H, Jin J, Yu W. Zhu Y, et al. Exp Hematol Oncol. 2022 Sep 16;11(1):57. doi: 10.1186/s40164-022-00314-w. Exp Hematol Oncol. 2022. PMID: 36114573 Free PMC article.
Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.
Zhai Y, Zhou X, Wang X. Zhai Y, et al. Ther Adv Med Oncol. 2022 May 4;14:17588359221093745. doi: 10.1177/17588359221093745. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35558005 Free PMC article. Review.

See all "Cited by" articles

References

1. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014;16(1):57–66. doi: 10.1016/S1470-2045(14)71170-2. - DOI - PubMed
1. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753. doi: 10.1056/NEJMoa1509277. - DOI - PMC - PubMed
1. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst H-A, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783. - DOI - PMC - PubMed
1. Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12(1):94. doi: 10.1186/s13045-019-0786-6. - DOI - PMC - PubMed
1. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0. - DOI - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014;16(1):57–66. doi: 10.1016/S1470-2045(14)71170-2. - DOI - PubMed

[2] Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2014;16(1):57–66. doi: 10.1016/S1470-2045(14)71170-2. - DOI - PubMed

[3] Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753. doi: 10.1056/NEJMoa1509277. - DOI - PMC - PubMed

[4] Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753. doi: 10.1056/NEJMoa1509277. - DOI - PMC - PubMed

[5] Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst H-A, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783. - DOI - PMC - PubMed

[6] Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst H-A, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783. - DOI - PMC - PubMed

[7] Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12(1):94. doi: 10.1186/s13045-019-0786-6. - DOI - PMC - PubMed

[8] Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12(1):94. doi: 10.1186/s13045-019-0786-6. - DOI - PMC - PubMed

[9] Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0. - DOI - PubMed

[10] Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Affiliations

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous